Maiwald

Eva Ehlich and Anja Fux of Maiwald summarise an EPO board ruling relating to substances and compositions in the context of medical use claims and how it could affect applicants’ portfolio strategies

While some observers are of the view that an Enlarged Board of Appeal ruling failed to provide sufficient clarity, Eva Ehlich and Anja Fux of Maiwald say the picture concerning post-published evidence is becoming clearer

Susanna Heurung of Maiwald welcomes a decision by the Board of Appeal regarding the extension of a grace period for use where the applicant’s bad faith was obvious

In concluding a two-part series on springboard injunctions, Marco Stief of Maiwald takes a deeper dive to explain their requirements, review case law, and examine their relevance in the pharmaceutical and life sciences sectors

In the first of two articles on the springboard doctrine, Marco Stief of Maiwald explains how the protective effect of a patent can continue to have an impact after the term of protection has ended

Gisela Grabow of Maiwald considers the potential changes to the EU’s general pharmaceutical legislation under a recent proposal, and the main questions raised for stakeholders